Early Esophageal Cancer And Pre Cancer Eliminated With Non Surgical Treatment Combination BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, announced the publication of two related European trials which report a 100% eradication rate for early esophageal cancer and pre-cancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system.
Source: www.medicalnewstoday.comMicrorobots Created Using Mechanical Locomotion Principles From Jumping Insects Researchers from the Laboratory of Intelligent Systems at EPFL unveiled a novel, grasshopper-inspired jumping robot at the IEEE International Conference on Robotics and Automation in Pasadena, California. The robot weighs a miniscule 7 grams, and can jump 1.4 meters, or more than 27 times its body size - ten times farther for its size and weight than any existing jumping robot.
Source: www.medicalnewstoday.comHIV Patients Suffer More From Osteoporosis Following the introduction of HAART (Highly Active Antiretroviral Therapy), the survival and quality of life for people infected with the human immunodeficiency virus (HIV-1) have increased in the resource-rich countries. However, with this improved prognosis an increase in long term negative disorders has been observed, namely osteoporosis (the gradual loss of bone mass).
Source: www.medicalnewstoday.comCirculation: Heart Failure: New Journal Focuses On Progress, Problems In Treating Heart Failure Findings about how the day of admission influences the length of a patient's hospitalization for heart failure, and questions about the effectiveness of two
drugs to treat heart failure patients are featured in the inaugural issue of Circulation: Heart Failure.
Source: www.medicalnewstoday.comIronwood Pharmaceuticals And Forest Laboratories Announce Presentation Of Linaclotide Phase 2b Chronic Constipation Study Results Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled study assessing the safety and efficacy of linaclotide in patients with chronic constipation (CC). Analysis of these data indicate that linaclotide met its primary endpoint.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 6:00 PM
